CJC-1295 NO DAC + IPAMORELIN BLEND (5mg + 5mg)

CJC-1295 + Ipamorelin Blend (5mg + 5mg) for comprehensive GH axis research. (99%) Purity verified here on Australian soil at The University of Melbourne.

This blend combines a modified GHRH analogue (CJC-1295 No DAC) with a selective growth hormone secretagogue (Ipamorelin) in a single vial, allowing researchers to study both GHRH and GHS receptor pathways simultaneously with accurate dosing and simplified preparation.

CJC-1295 No DAC (Mod GRF 1-29) is a stabilised GHRH analogue with four amino acid substitutions (D-Ala², Gln⁸, Ala¹⁵, Leu²⁷) that protect against DPP-IV degradation. It works by stimulating the GHRH receptor on pituitary somatotrophs to promote GH synthesis and release.

Ipamorelin is a synthetic pentapeptide that acts as a selective agonist at the GHS-R1a receptor. Research has characterised it as one of the most selective growth hormone secretagogues, with minimal effects on cortisol and prolactin compared to earlier generation compounds like GHRP-6.

The combination of these two peptides allows research into potential synergistic effects on the GH axis. Studies have investigated whether GHRH analogues and secretagogues produce additive or synergistic GH release when administered together, as they work through complementary receptor mechanisms.

Gen Ex Peptides supplies this blend tested at an Australian university laboratory not generic overseas certificates. Each component is verified for purity (99%) using HPLC and mass spectrometry.